Literature DB >> 11726546

Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi.

S Goto1, Y Ihara, Y Urata, S Izumi, K Abe, T Koji, T Kondo.   

Abstract

Glutathione S-transferase (GST) functions in xenobiotic biotransformation and drug metabolism. Increased expression of GSTpi, an isozyme of GST, has been found in cancer cells resistant to doxorubicin hydrochloride (DOX) or cis-diamminedichloroplatinum (II) (CDDP), and this increase was believed to be correlated with drug resistance of cancer cells. GST is mainly expressed in the cytoplasm; GSTpi in the nucleus has been reported in cancer cells, but the meaning of this result is not known. Here, we studied changes in the amount of nuclear GSTpi after exposure of cancer cells to anticancer drugs, and role of the nuclear GSTpi in drug resistance. We found nuclear GSTpi in cancer cells resistant to DOX, and the amount of nuclear GSTpi was enhanced by treatment of the cancer cells with DOX or CDDP. We also found that a mushroom lectin, an inhibitor of nuclear transport, inhibited the nuclear transfer of GSTpi, suggesting the existence of a specific transport system for the nuclear transfer of GSTpi. Nuclear GSTpi protected DNA against damage by anticancer drugs. These results suggest a possible role of GSTpi in the acquisition of resistance to anticancer drugs by cancer cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11726546     DOI: 10.1096/fj.01-0376com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  14 in total

1.  Proteomic analysis of glutathione S-transferase isoforms in mouse liver mitochondria.

Authors:  Hai-Dan Sun; Ya-Wei Ru; Dong-Juan Zhang; Song-Yue Yin; Liang Yin; Ying-Ying Xie; You-Fei Guan; Si-Qi Liu
Journal:  World J Gastroenterol       Date:  2012-07-14       Impact factor: 5.742

Review 2.  Redox control systems in the nucleus: mechanisms and functions.

Authors:  Young-Mi Go; Dean P Jones
Journal:  Antioxid Redox Signal       Date:  2010-08-15       Impact factor: 8.401

3.  Hypoxia can impair doxorubicin resistance of non-small cell lung cancer cells by inhibiting MRP1 and P-gp expression and boosting the chemosensitizing effects of MRP1 and P-gp blockers.

Authors:  Yu-Lun Chen; Tsung-Ying Yang; Kun-Chieh Chen; Chieh-Liang Wu; Shih-Lan Hsu; Chi-Mei Hsueh
Journal:  Cell Oncol (Dordr)       Date:  2016-06-15       Impact factor: 6.730

4.  Investigation of interactions of doxorubicin with purine nucleobases by molecular modeling.

Authors:  Esra Şahin Akdeniz; Cenk Selçuki
Journal:  J Mol Model       Date:  2022-02-26       Impact factor: 1.810

5.  GSTpi reduces DNA damage and cell death by regulating the ubiquitination and nuclear translocation of NBS1.

Authors:  Jinyi Zhou; Lili Gu; Yingying Shi; Ting Huang; Xirui Fan; Xiaowen Bi; Shuai Lu; Juanjuan Liang; Lan Luo; Peng Cao; Zhimin Yin
Journal:  Cell Mol Life Sci       Date:  2021-12-22       Impact factor: 9.261

6.  Human osteosarcoma xenografts and their sensitivity to chemotherapy.

Authors:  Skjalg Bruheim; Oyvind S Bruland; Knut Breistol; Gunhild M Maelandsmo; Oystein Fodstad
Journal:  Pathol Oncol Res       Date:  2004-09-25       Impact factor: 3.201

7.  Functional activities and immunohistochemical cellular distribution of glutathione s-transferases in normal, dysplastic, and squamous cell carcinoma human oral tissues.

Authors:  Peter J Giannini; Mark A Morse; Christopher M Weghorst; Ping Pei; Susan R Mallery
Journal:  Clin Med Oncol       Date:  2008-03-28

8.  Modulation of DNA intercalation by resveratrol and genistein.

Authors:  Subbiah Usha; Irudayam Maria Johnson; Raghunathan Malathi
Journal:  Mol Cell Biochem       Date:  2006-03       Impact factor: 3.396

9.  Pleiotropic functions of glutathione S-transferase P.

Authors:  Jie Zhang; Christina Grek; Zhi-Wei Ye; Yefim Manevich; Kenneth D Tew; Danyelle M Townsend
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

10.  tRNA binding to antitumor drug doxorubicin and its analogue.

Authors:  Daniel Agudelo; Philippe Bourassa; Marc Beauregard; Gervais Bérubé; Heidar-Ali Tajmir-Riahi
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.